特任教授，博士生导师，入选国家海外高层次人才引进计划，免疫应答与免疫治疗重点实验室、微尺度物质科学国家研究中心、中国科学院天然免疫与慢性疾病重点实验室、安徽省新发突发传染病重点实验室PI。多年来一直致力于人体共生菌群与健康和疾病的相关研究，学术成果以第一或通讯作者身份发表于Nature、Nature Communications、Nature Reviews Gastroenterology & Hepatology、Journal of Hepatology、Gut等高影响因子期刊，并被Nature、Science、Cell、Nature Reviews Drug Discovery、Nature Reviews Gastroenterology & Hepatology、Cell Host & Microbe，Hepatology等国际著名刊物点评报道，获得Faculty of 1000收录并被两位独立推荐人分别给予最高等级评价。迄今共发表SCI论文35篇（其中17篇IF>10），申请发明专利1项，相关成果被引用2700余次，单篇最高被引485次。受邀参加多场国际国内学术交流会议并做口头报告，担任iMeta，mLife等期刊编辑和Nature Communications，Science Advances等期刊审稿人，受邀担任中国生物工程学会噬菌体专业技术委员会首任委员。
教育及工作经历：
2022年-至今 中国科学技术大学生命科学与医学部，教授，博士生导师
2017-2022年 美国加利福尼亚大学圣地亚哥分校医学院，博士后研究学者
2011-2016年 美国德州农工大学生物化学与生物物理系，获生物化学博士学位
2007-2011年 中国科学技术大学生命科学学院，获生物科学学士学位
主要研究兴趣：
人体肠道内存在着超过1000种，与人体自身细胞数量相当的微生物种群。这一人体“最大的器官”，携带着百倍于人体自身基因数量的“第二套基因组”，在维持机体健康方面发挥着不可或缺的作用。大量研究表明，肠道菌群紊乱与包括消化系统疾病、神经系统疾病等在内的多种人体疾病，具有显著相关性。深入探究其具体的分子致病机理，并据此开发相应的新型诊疗策略和方法，具有重要的科学意义和临床价值。
噬菌体是细菌的天然宿敌。它们只侵染细菌而不感染动物细胞，具有高度的宿主特异性。在抗生素耐药问题日益严峻的今天，噬菌体疗法正受到越来越多的关注，成为当今微生物学研究领域的前沿热点方向之一。利用噬菌体还可以对肠道细菌进行“精准打击，定点清除”，为精准编辑肠道菌群提供了一条可行的思路，从而为菌群相关的人体疾病新型生物疗法的开发，奠定坚实的基础。
课题组围绕“肠道微生物与人体健康”这一主题，主要开展以下方面的研究：
1. 肠道微生物对代谢性及免疫性疾病，尤其是慢性肝病的影响及其具体分子机制；
2. 微生物相关生物疗法，尤其是噬菌体疗法的开发及应用；
3. 肠道微生物研究相关新技术与新方法的研制开发。
代表性论著（#共同第一作者，*通讯作者）：
1. Duan Y#, Llorente C#, Lang S, Brandl K, Chu H, Jiang L, et al. (2019). Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease. Nature. 575(7783): 505-511. doi: 10.1038/s41586-019-1742-x.
Recommended by Faculty of 1000 (Two recommendations from two independent experts). https:/f1000.com/prime/736896846; Featured article and highlighted in Nature, Science, Cell, Nature Reviews Drug Discovery, Nature Reviews Gastroenterology & Hepatology, Hepatology and Environmental Microbiology:
Microbial clues to a liver disease. Nature. doi: 10.1038/d41586-019-03417-3
Toxic gut bacteria make alcohol-triggered liver disease more deadly. Science. doi: 10.1126/science.aba2064
Bacteriophage prevents alcoholic liver disease. Cell. doi: 10.1016/j.cell.2019.12.034
Phages fight alcoholic hepatitis. Nature Reviews Drug Discovery. doi: 10.1038/d41573-019-00198-2
Manipulating the gut microbiota to combat alcoholic hepatitis. Nature Reviews Gastroenterology & Hepatology. doi: 10.1038/s41575-019-0246-3
Phage therapy for alcoholic hepatitis. Hepatology. doi: 10.1002/hep.31623
Hope for alcoholics from phage therapy? Environmental Microbiology. doi: 10.1111/1462-2920.14898
2. Xie S#, Li J#, Lyu F#, Xiong Q#, et al., Duan Y*, Jiang Y*, Zhou H*, Chen P*. (2023). Novel tripeptide RKH derived from Akkermansia muciniphila protects against lethal sepsis. Gut. 14(3):490. doi: 10.1136/gutjnl-2023-329996.
3. Chen X#, Mendes BG#, Alves BS, Duan Y*. (2023). Phage therapy in gut microbiome. Progress in Molecular Biology and Translational Science. doi: 10.1016/bs.pmbts.2023.04.005.
4. Duan Y, Young R, Schnabl B. (2022). Bacteriophages and their potential for treatment of gastrointestinal diseases. Nature Reviews Gastroenterology & Hepatology. 19(2):135-144. doi: 10.1038/s41575-021-00536-z.
5. Mendes BG#, Duan Y#, Schnabl B. (2022). Immune response of an oral Enterococcus faecalis phage cocktail in a mouse model of ethanol-induced liver disease. Viruses. 14(3):490. doi: 10.3390/v14030490.
6. Duan Y#, Chu H#, Brandl K, Jiang L, Zeng S, Mendes BG, et al. (2021). CRIg on liver macrophages clears pathobionts and protects against alcoholic liver disease. Nature Communications. 12(1):7172. doi: 10.1038/s41467-021-27385-3.
7. Chu H#, Duan Y#, Lang S, Jiang L, Wang Y, Llorente C, et al. (2020). The Candida albicans exotoxin Candidalysin promotes alcohol-associated liver disease. Journal of Hepatology. 72(3):391-400. doi: 10.1016/j.jhep.2019.09.029. (2019 AASLD Early Career Investigator Award)
8. Gao B#, Duan Y#, Lang S, Barupal D, Wu TC, Valdiviez L, et al. (2020). Functional microbiomics reveals alterations of the gut microbiome and host co-metabolism in patients with alcoholic hepatitis. Hepatology Communications. 4(8):1168-1182. doi: 10.1002/hep4.1537. (Journal Cover)
9.Duan Y, Huey JD, Herman JK (2016). The DnaA inhibitor SirA acts in the same pathway as Soj (ParA) to facilitate oriC segregation during Bacillus subtilis sporulation. Molecular Microbiology. 102(3):530-544. doi: 10.1111/mmi.13477.
10. Duan Y#, Sperber AM#, Herman JK (2016). YodL and YisK possess shape-modifying activities that are suppressed by mutations in Bacillus subtilismreB and mbl. Journal of Bacteriology. 198(15):2074-2088. doi: 10.1128/JB.00183-16.
11. Zeng S, Rosati E, Saggau C, Messner B, Chu H, Duan Y, Hartmann P, et al.(2023). Candida albicans-specific Th17 cell-mediated response contributes to alcohol-associated liver disease. Cell Host Microbe. 31(3):389-404. doi:10.1016/j.chom.2023.02.001.
12. Demir M#, Lang S#, Hartmann P#, Duan Y, Martin A, Miyamoto Y, Bondareva M, et al. (2022). The fecal mycobiome in non-alcoholic fatty liver disease. Journal of Hepatology. 76(4):788-799. doi: 10.1016/j.jhep.2021.11.029.
13. Hsu CL,Duan Y, Fouts DE, Schnabl B. (2021). Intestinal virome and therapeutic potential of bacteriophages in liver disease. Journal of Hepatology. 75(6):1465-1475. doi: 10.1016/j.jhep.2021.08.003.
14. Zhang Q, Ma C, Duan Y, Heinrich B, Rosato U, Diggs L, et al. (2021). Gut microbiome directs hepatocytes to recruit MDSC and promote cholangiocarcinoma. Cancer Discovery. 11(5):1248-1267. doi: 10.1158/2159-8290.CD-20-0304.
15. Jiang L#, Lang S#, Duan Y, Zhang X, Gao B, Chopyk J, et al. (2020). Intestinal virome in patients with alcoholic hepatitis. Hepatology. 72(6):2182-2196. doi: 10.1002/hep.31459.
16. Lang S, Duan Y, Liu J, Torralba MG, Kuelbs C, Ventura-Cots M, et al. (2020). Intestinal fungal dysbiosis and systemic immune response to fungi in patients with alcoholic hepatitis. Hepatology. 71(2):522-538. doi: 10.1002/hep.30832. (IF=17.425)
17. Lang S#, Demir M#, Martin A, Jiang L, Zhang X, Duan Y, Gao B, Wisplinghoff H, et al. (2020). Intestinal virome signature associated with severity of nonalcoholic fatty liver disease. Gastroenterology. 159(5):1839-1852. doi: 10.1053/j.gastro.2020.07.005.
18. Hendrikx T, Duan Y, Wang Y, Oh JH, Alexander LM, Huang W, et al. (2019). Bacteria engineered to produce IL-22 in intestine induce expression of REG3G to reduce ethanol-induced liver disease in mice. Gut. 68(8):1504-1515. doi: 10.1136/gutjnl-2018-317232.
19. Chu H, Duan Y, Yang L, and Schnabl B (2019). Small Metabolites, possible big changes: a microbiota-centered view of non-alcoholic fatty liver disease. Gut. 68(2):359-370. doi: 10.1136/gutjnl-2018-316307.
完整论文列表请见:Google Scholar: https://scholar.google.com/citations?user=ACzdWz8AAAAJ&hl=en
招生招聘：
课题组诚聘具有微生物学、免疫学、细胞生物学、生物信息学、合成生物学等相关研究背景的博士后及特任副研究员，待遇从优；同时热忱欢迎对微生物与人体健康感兴趣的本科生加入课题组进行本科实习，及攻读硕士、博士学位。
联系方式：
Email:yduan@ustc.edu.cn